Daiichi Pharmaceutical Co., Ltd.

Other

Daiichi Sankyo Company, Limited

Drug Delivery System Institute, Ltd.

Hiroshi Kuga

Kazuhiro Inoue

Hiroshi Susaki

Masahiro Ikeda

Eiji Kumazawa

Yoshinobu Shiose

Akiko Togo

Takeshi Masuda

Satoru Yasuda

Hiroshi Korenaga

Masako Soma

Junko Kawamura

Hiromi Ishibashi

A protein that recognizes a drug moiety of an antibody-drug conjugate in which a drug represented by the following formula is conjugated to an antibody via a linker, and a method for quantifying the concentration in plasma of an antibody-drug conjugate in a mammal to which the antibody-drug conjugate has been administered, by using the protein, and a method for identifying a tissue distribution of an antibody-drug conjugate.

Protein recognizing drug moiety of antibody-drug conjugate

A DDS compound comprising a carboxy(C)alkyldextran polyalcohol modified with a saccharide compound and a residue of drug compound bound to the carboxy(C)alkyldextran polyalcohol, and a method for measuring a DDS compound in which a polymer carrier and a residue of drug compound are bound to each other by means of a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises the steps of treating the DDS compound with a peptidase, and measuring the resulting hydrolysate.

DDS compound and method for measurement thereof

A drug complex characterized in that a residue of a drug compound such as antineoplastic agents and a carboxy(C)alkyldextran polyalcohol obtained by treating a dextran under conditions that enable substantially complete polyalcoholization are bound to each other by means of a spacer comprising an amino acid or a spacer comprising peptide-bonded 2 to 8 amino acids. Said complex is characterized in that it has excellent selectivity to tumorous sites so as to exhibit high antineoplastic activity and also achieves reduced appearance of toxicity.

Drug complex

A drug complex useful as a DDS compound, which is represented by the following formula: A-R&mdash;NH&mdash;Y&mdash;CH &mdash;O&mdash;CO-Q, wherein A is a polymer as a drug carrier; R is a spacer, wherein the spacer is an amino acid or an oligopeptide comprising 2 to 8 amino acids; Y is phenylene group which may be substituted; and Q is a residue of a drug compound such as antineoplastic agents. The complex provides rapid and site-selective release of a drug compound such as antineoplastic or anti-inflammatory agents and surely exhibits expected efficacy.

Drug complex and drug delivery system

A drug delivery system compound comprising a carboxy(C )alkyldextran polyalcohol modified with a saccharide compound and a residue of drug compound bound to the carboxy(C )alkyldextran polyalcohol, and a method for measuring a drug delivery system compound in which a polymer carrier and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase, and measuring the resulting hydrolysate.

DDS compounds and method for assaying the same

A drug complex characterized in that a residue of a drug compound such as antineoplastic agents and a carboxy(C )alkyldextran polyalcohol obtained by treating a dextran under conditions that enable substantially complete polyalcoholization are bound to each other by means of a spacer comprising an amino acid or a spacer comprising peptide-bonded 2 to 8 amino acids. Said complex is characterized-in that it has excellent selectivity to tumorous sites so as to exhibit high antineoplastic activity and also achieves reduced appearance of toxicity.

Growing community of inventors

Tokyo, Japan

Hiroshi Kuga